In a murine model of systemic sclerosis, BTKB66 (a new BTK inhibitor) treatment resulted in a reduction in skin fibrosis, collagen deposition, and decreased inflammatory cell infiltration in the skin [133]. The gene discussed is BTK; the disease is systemic sclerosis.